Public biotechnology company (Nasdaq: NXTC)
Appears in 1 story · Last updated Jul 14, 2026
As of July 2026: Public shell providing the Nasdaq listing; winding down its own drugs
The team that built Akero Therapeutics and sold it to Novo Nordisk for up to $5.2 billion has a second act. On Tuesday, their new startup, Avere Therapeutics, agreed to merge with struggling public biotech NextCure and raised $320 million to fund it.
Updated Jul 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
